WO2011043830A3 - Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih - Google Patents
Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih Download PDFInfo
- Publication number
- WO2011043830A3 WO2011043830A3 PCT/US2010/002727 US2010002727W WO2011043830A3 WO 2011043830 A3 WO2011043830 A3 WO 2011043830A3 US 2010002727 W US2010002727 W US 2010002727W WO 2011043830 A3 WO2011043830 A3 WO 2011043830A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- peptides
- immune response
- methods
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne l'amélioration, la modulation ou la stimulation de la réponse immunitaire innée contre le VIH-1 et d'autres pathogènes viraux. Elle concerne en outre la modulation et l'application de modulateurs immunitaires et de peptides pour des vaccins contre le VIH-1 et contre d'autres pathogènes. L'invention concerne des procédés et des moyens destinés à activer une réponse innée contre le VIH-1 en utilisant ou via le peptide ou la protéine de capside du VIH, comprenant la modulation de la liaison de la cyclophiline A à la protéine de capside du VIH et la modulation de la capacité du VIH à activer le facteur de transcription inné majeur IRF3 et l'interféron. La présente invention concerne en outre des procédés et des tests de criblage de composés, d'agents, ou de peptides capables d'améliorer ou d'activer une réponse immunitaire innée, particulièrement contre le VIH-1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10822366.0A EP2485759A4 (fr) | 2009-10-09 | 2010-10-12 | Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27875909P | 2009-10-09 | 2009-10-09 | |
US61/278,759 | 2009-10-09 | ||
US40233610P | 2010-08-27 | 2010-08-27 | |
US61/402,336 | 2010-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011043830A2 WO2011043830A2 (fr) | 2011-04-14 |
WO2011043830A3 true WO2011043830A3 (fr) | 2011-06-16 |
Family
ID=43857331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/002727 WO2011043830A2 (fr) | 2009-10-09 | 2010-10-12 | Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih |
Country Status (3)
Country | Link |
---|---|
US (1) | US9358281B2 (fr) |
EP (1) | EP2485759A4 (fr) |
WO (1) | WO2011043830A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9037247B2 (en) * | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
WO2012168480A1 (fr) * | 2011-06-10 | 2012-12-13 | Institut Curie | Agents et procédés pour la production d'adjuvants non infectieux dérivés de capsides de vih |
US9149519B2 (en) | 2012-01-17 | 2015-10-06 | New York University | Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain |
EP3134107B1 (fr) * | 2014-04-24 | 2020-05-27 | Janssen Sciences Ireland Unlimited Company | Utilisation d'une protéine accessoire dérivée du vih pour la réactivation du vih latent |
CA2954056C (fr) | 2014-07-11 | 2020-04-28 | Gilead Sciences, Inc. | Modulateurs de recepteurs de type toll pour le traitement du vih |
JP7176737B2 (ja) * | 2016-02-15 | 2022-11-22 | テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | レトロウイルス核酸配列の切除 |
US20220175938A1 (en) * | 2019-08-01 | 2022-06-09 | Massachusetts Institute Of Technology | Poly(Beta-Thioester) Polymers and Polymeric Nanoparticles |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773225A (en) * | 1994-05-24 | 1998-06-30 | The Trustees Of Columbia University In The City Of New York | Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation |
US5840305A (en) * | 1996-03-14 | 1998-11-24 | The Picower Institute For Medical Research | Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity |
US20060257974A1 (en) * | 2002-05-16 | 2006-11-16 | Bavarian Nordic A/S | Fusion proteins of HIV regulatory/accessory proteins |
US20070104690A1 (en) * | 1996-10-17 | 2007-05-10 | Kingsman Alan J | Retroviral vectors |
US20080045454A1 (en) * | 2004-07-06 | 2008-02-21 | Jeremy Luban | Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same |
WO2009026183A1 (fr) * | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Utilisation de protéines gag vih/vis chimériques pour optimiser des réponses de lymphocytes t induites par vaccin contre le gag du vih |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002362368B2 (en) * | 2001-09-20 | 2006-09-21 | Glaxo Group Limited | HIV-gag codon-optimised DNA vaccines |
GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
ES2543084T3 (es) * | 2003-02-18 | 2015-08-14 | Baylor College Of Medicine | Activación inducida en células dendríticas |
US20080107683A1 (en) * | 2004-11-30 | 2008-05-08 | David Hone | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
US7803582B2 (en) * | 2007-03-17 | 2010-09-28 | Hongzhan Xu | Recombinant vector and use in gene therapy |
-
2010
- 2010-10-12 US US12/925,068 patent/US9358281B2/en active Active
- 2010-10-12 WO PCT/US2010/002727 patent/WO2011043830A2/fr active Application Filing
- 2010-10-12 EP EP10822366.0A patent/EP2485759A4/fr not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773225A (en) * | 1994-05-24 | 1998-06-30 | The Trustees Of Columbia University In The City Of New York | Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation |
US5840305A (en) * | 1996-03-14 | 1998-11-24 | The Picower Institute For Medical Research | Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity |
US20070104690A1 (en) * | 1996-10-17 | 2007-05-10 | Kingsman Alan J | Retroviral vectors |
US20060257974A1 (en) * | 2002-05-16 | 2006-11-16 | Bavarian Nordic A/S | Fusion proteins of HIV regulatory/accessory proteins |
US20080045454A1 (en) * | 2004-07-06 | 2008-02-21 | Jeremy Luban | Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same |
WO2009026183A1 (fr) * | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Utilisation de protéines gag vih/vis chimériques pour optimiser des réponses de lymphocytes t induites par vaccin contre le gag du vih |
Non-Patent Citations (3)
Title |
---|
COLGAN ET AL.: "Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.", J. VIROL., vol. 70, no. 7, July 1996 (1996-07-01), pages 4299 - 4310, XP008155876 * |
GATANAGA ET AL.: "Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.", J. BIOL. CHEM., vol. 281, no. 2, 2006, pages 1241 - 1250, XP008155875 * |
See also references of EP2485759A4 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011043830A2 (fr) | 2011-04-14 |
EP2485759A4 (fr) | 2013-07-24 |
US20110159025A1 (en) | 2011-06-30 |
EP2485759A2 (fr) | 2012-08-15 |
US9358281B2 (en) | 2016-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011043830A3 (fr) | Procédés, agents et peptides destinés à induire une réponse immunitaire innée dans la vaccination contre le vih | |
MX346862B (es) | Secuencias consenso de envoltura de vih y método para usar las mismas. | |
PH12015500931A1 (en) | Recombinant particle based vaccines against human cytomegalovirus infection | |
MX350274B (es) | Vacunas para hsv-2. | |
EA202090149A1 (ru) | Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения | |
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
EP3967323A3 (fr) | Vaccin contre le vih | |
WO2007147529A3 (fr) | Vaccin viral recombinant | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
WO2009124312A3 (fr) | Séquences consensus de protéines du virus chikungunya, molécules d’acide nucléique codant pour celles-ci, et compositions et procédés d’utilisation de celles-ci | |
TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
AR071910A1 (es) | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. | |
WO2007095320A3 (fr) | Antigènes du papillomavirus humain, compositions de vaccin et méthodes | |
EA202090759A3 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
MY162335A (en) | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof | |
MY149395A (en) | Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus | |
WO2016191641A3 (fr) | Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus | |
WO2016090035A3 (fr) | Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
WO2011038473A8 (fr) | Méthode, trousse, plasmide et composition pour induire une réponse immunitaire contre le virus de la dengue, au moyen de vaccins à adn et de virus chimériques | |
MX2017014417A (es) | Vacunas contra el dengue. | |
WO2010040572A3 (fr) | Anticorps | |
EP2632942A4 (fr) | Protéine d'enveloppe recombinante du virus de l'immunodéficience humaine (vih) et vaccin la contenant | |
WO2010040136A3 (fr) | Sélection d'antigènes pour vaccin contre le vih, par l'utilisation de la variation de séquence intrapatient en vue d'identifier des mutations dans la glycoprotéine de l'enveloppe du vih qui affectent la liaison d'anticorps neutralisants à large spectre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10822366 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010822366 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010822366 Country of ref document: EP |